TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) was up 9.6% during mid-day trading on Friday after Oppenheimer raised their price target on the stock from $40.00 to $45.00. Oppenheimer currently has an outperform rating on the stock. TransMedics Group traded as high as $45.38 and last traded at $45.17. Approximately 25,164 shares were traded during trading, a decline of 93% from the average daily volume of 374,697 shares. The stock had previously closed at $41.21.
TMDX has been the subject of a number of other reports. JPMorgan Chase & Co. raised TransMedics Group from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $26.00 to $48.00 in a research note on Tuesday. Canaccord Genuity Group increased their target price on TransMedics Group from $46.00 to $58.00 in a research note on Thursday. Cowen increased their target price on TransMedics Group from $45.00 to $50.00 in a research note on Tuesday. Cowen raised their price target on shares of TransMedics Group from $39.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 26th. Finally, Morgan Stanley raised their price target on shares of TransMedics Group from $34.00 to $37.00 and gave the stock an “equal weight” rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus price target of $46.00.
In other news, Director James R. Tobin sold 48,515 shares of the stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $35.00, for a total value of $1,698,025.00. Following the completion of the sale, the director now owns 302,106 shares of the company’s stock, valued at approximately $10,573,710. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other TransMedics Group news, VP John F. Carey sold 1,500 shares of the firm’s stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $28.19, for a total transaction of $42,285.00. Following the completion of the sale, the vice president now owns 379 shares of the company’s stock, valued at approximately $10,684.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James R. Tobin sold 48,515 shares of the firm’s stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $35.00, for a total value of $1,698,025.00. Following the sale, the director now directly owns 302,106 shares of the company’s stock, valued at approximately $10,573,710. The disclosure for this sale can be found here. In the last 90 days, insiders sold 151,814 shares of company stock valued at $5,633,336. 8.70% of the stock is owned by insiders.
Institutional Investors Weigh In On TransMedics Group
TransMedics Group Stock Up 18.4 %
The company has a debt-to-equity ratio of 0.59, a current ratio of 5.22 and a quick ratio of 4.40. The company has a market cap of $1.36 billion, a P/E ratio of -28.36 and a beta of 1.63. The stock has a 50-day moving average of $32.37 and a 200 day moving average of $25.13.
TransMedics Group (NASDAQ:TMDX – Get Rating) last issued its quarterly earnings results on Monday, August 1st. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.09). TransMedics Group had a negative return on equity of 69.38% and a negative net margin of 92.76%. During the same period in the prior year, the firm posted ($0.39) earnings per share. Research analysts anticipate that TransMedics Group, Inc. will post -1.58 earnings per share for the current year.
About TransMedics Group
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
- Get a free copy of the StockNews.com research report on TransMedics Group (TMDX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.